Cargando…
Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
The fibroblast growth factor (FGF) signaling cascade is a key signaling pathway in hepatocarcinogenesis. We report high FGF receptor (FGFR) expression in 17.7% (11 of 62) of hepatocellular carcinoma (HCC) models. Infigratinib, a pan‐FGFR inhibitor, potently suppresses the growth of high‐FGFR‐express...
Autores principales: | Huynh, Hung, Lee, Liek Yeow, Goh, Kah Yong, Ong, Richard, Hao, Huai‐Xiang, Huang, Alan, Wang, Youzhen, Graus Porta, Diana, Chow, Pierce, Chung, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635738/ https://www.ncbi.nlm.nih.gov/pubmed/30575985 http://dx.doi.org/10.1002/hep.30481 |
Ejemplares similares
-
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2020) -
Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020) -
Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021) -
Correction to: Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021) -
Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)